Screening for antibodies against the CV2 antigen is used in the investigation of patients with possible paraneoplastic syndrome.
Antibodies against the CV2 antigen are a paraneoplastic marker that is mainly associated with small cell lung cancer but can also be found in patients with thymoma and other types of tumors. Clinical symptoms may include chorea, sensor-motor neuropathy, limbic encephalitis, and cerebral degeneration. Neurological symptoms can precede the diagnosis of cancer up to five years earlier.
See also: Anti-Neuronal Antibodies